相似文献
1
Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
Eur Respir J. 2022 Aug 25;60(2). doi: 10.1183/13993003.01227-2022. Print 2022 Aug.
2
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
Am J Respir Crit Care Med. 2009 Dec 1;180(11):1151-7. doi: 10.1164/rccm.200905-0795OC. Epub 2009 Sep 3.
3
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93. doi: 10.1164/rccm.200807-1029OC. Epub 2008 Aug 21.
4
Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
BMC Infect Dis. 2017 Feb 14;17(1):146. doi: 10.1186/s12879-017-2245-8.
5
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
Lancet. 1999 May 29;353(9167):1843-7. doi: 10.1016/s0140-6736(98)11467-8.
6
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Am J Respir Crit Care Med. 2011 May 1;183(9):1254-61. doi: 10.1164/rccm.201012-1949OC. Epub 2011 Feb 17.
7
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Lancet HIV. 2020 Jun;7(6):e401-e409. doi: 10.1016/S2352-3018(20)30032-1. Epub 2020 Mar 30.
8
Treatment of latent tuberculosis infection.
Ther Adv Respir Dis. 2013 Dec;7(6):351-6. doi: 10.1177/1753465813503028. Epub 2013 Sep 20.
9
Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.
Am J Prev Med. 2018 Aug;55(2):244-252. doi: 10.1016/j.amepre.2018.04.030. Epub 2018 Jun 14.
10
Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
PLoS One. 2011;6(7):e22276. doi: 10.1371/journal.pone.0022276. Epub 2011 Jul 18.
引用本文的文献
1
Identification of Factors Determining Patterns of Serum C-Reactive Protein Level Reduction in Response to Treatment Initiation in Patients with Drug-Susceptible Pulmonary Tuberculosis.
Antibiotics (Basel). 2024 Dec 14;13(12):1216. doi: 10.3390/antibiotics13121216.
2
TB prevention activities in the WHO European Region.
IJTLD Open. 2024 Aug 1;1(8):349-354. doi: 10.5588/ijtldopen.24.0350. eCollection 2024 Aug.
3
Pharmacists' Role in Global TB Elimination: Practices, Pitfalls, and Potential.
Healthcare (Basel). 2024 Jun 3;12(11):1137. doi: 10.3390/healthcare12111137.
4
Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
Euro Surveill. 2024 Apr;29(17). doi: 10.2807/1560-7917.ES.2024.29.17.2400211.
本文引用的文献
1
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
Eur Respir J. 2022 May 19;59(5). doi: 10.1183/13993003.00388-2022. Print 2022 May.
Zotero 插件